The role of liver biopsy in the management of chronic hepatitis C;Place de la ponction-biopsie hépatique dans la príse en charge del l'hépatite chronique C

Gastroenterologie Clinique et Biologique

Volumn 26, Issue SPEC. 2, 2002, Pages

  Nousbaum, Jean Baptiste ^a  

^a SERVICE DE RHUMATOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC HEPATITIS; CONFERENCE PAPER; HEMODIALYSIS; HEMOPHILIA; HEPATITIS C; HISTOPATHOLOGY; HUMAN; KIDNEY FAILURE; LIVER BIOPSY; LIVER FIBROSIS; LIVER TRANSPLANTATION; NON INVASIVE MEASUREMENT; PROGNOSIS; RISK ASSESSMENT;

BIOPSY; FEMALE; FIBROSIS; HEMOPHILIA A; HEPATITIS C, CHRONIC; HUMANS; KIDNEY FAILURE, CHRONIC; LIVER; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NECROSIS; PROGNOSIS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 0036258848     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (116)

1. Practices of liver biopsy in France: Results of a prospective nationwide survey
2. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
3. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C
4. Classification of chronic hepatitis: Diagnosis, grading and staging
5. Histological grading and staging in chronic hepatitis: Clinical applications and problems
6. An algorithm for the grading of activity in chronic hepatitis C
7. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
8. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
9. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
10. Classification of chronic viral hepatitis: A need for reassessment
11. The pathology of hepatitis C
12. Chronic hepatitis. An update on terminology and reporting
13. Histological grading and staging of chronic hepatitis
14. Clinical significance of portal lymphoid aggregates/follicles in Chinese patients with chronic hepatitis C
15. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis
16. Histopathology of hepatitis C virus infection
17. Pathological diagnosis of chronic hepatitis C: A multicenter comparative study with chronic hepatitis B
18. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: A comparative analysis
19. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity
20. The long-term pathological evolution of chronic hepatitis C
21. Predictive factors of fibrosis progression in patients with mild hepatitis C
22. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA
23. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C
24. Management of chronic hepatitis C: Clinical audit of biopsy based management algorithm
25. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy
26. Quantitation of hepatic hepatitis C virus RNA in patients with chronic hepatitis C. Relationship with severity of disease, viral genotype and response to treatment
27. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C
28. The inconvenience of investigations used in hepatology: Patients' and hepatologists' opinions
29. Pratique et attentes des médecins généralistes en matière d'hépatite C dans la région Auvergne
30. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
31. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C
32. Outpatient liver biopsy: How safe is it?
33. A 21-year experience with major hemorrhage after percutaneous liver biopsy
34. Outcome of patients hospitalized for complications after outpatient liver biopsy
35. Liver biopsy: Complications in 1,000 inpatients and outpatients
36. The role of ultrasonography and automatic-needle biopsy in outpatient percutaneous liver biopsy
37. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: An audit by the British Society of Gastroenterology and the Royal College of Physicians of London
38. Complications following percutaneous liver biopsy
39. Prospective study of the incidence of ultrasound-detected intrahepatic and subcapsular hematomas in patients randomized to 6 or 24 hours of bed rest after percutaneous liver biopsy
40. Pretreatment evaluation of chronic hepatitis C: Risks, benefits, and costs
41. Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy
42. Biopsy diagnosis of cirrhosis: Blind percutaneous versus guided direct vision techniques - A review
43. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver
44. Percutaneous blind biopsy versus laparoscopy with guided biopsy in diagnosis of cirrhosis. A prospective, randomized trial
45. Ultrasound-assisted percutaneous liver biopsy: Superiority of the Tru-Cut over the Menghini needle for diagnosis of cirrhosis
46. Transjugular liver biopsy: Comparison with percutaneous liver biopsy
47. Transvenous liver biopsy: An experience based on 1,000 hepatic tissue samplings with this procedure
48. Conférence de consensus. Texte court. Hépatite C: Dépistage et traitement
49. National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C
50. Easl International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement
51. Natural history of liver fibrosis progression in patients with chronic hepatitis C
52. Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: A comparison between immunocompetent and immunocompromised patients
53. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients
54. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: A long-term retrospective cohort study
55. Treatment of hepatitis C virus-related cirrhosis: A randomized, controlled trial of interferon alfa-2b versus no treatment
56. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
57. Appropriateness of liver biopsy
58. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alpha 2b
59. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha 2b for 60 weeks
60. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial
61. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial
62. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis
63. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: A multicenter randomized controlled trial from France
64. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis
65. The effect of interferon on the liver in chronic hepatitis C: A quantitative evaluation of histology by meta-analysis
66. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment
67. alpha-Interferon in the treatment of chronic viral hepatitis: Effects on fibrogenesis serum markers
68. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
69. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view
70. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy
71. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia
72. Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response: Results of a randomized trial
73. Maintenance interferon for chronic hepatitis C: More issues than answers?
74. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis
75. Comment et pourquoi rechercher la dysplasie hépatocytaire à grandes cellules sur ponction-biopsie hépatique?
76. Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center
77. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity
78. Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States
79. A longitudinal analysis of hepatitis C virus replication following liver transplantation
80. Long-term outcome of hepatitis C infection after liver transplantation
81. Recurrence of hepatitis C virus infection after liver transplantation
82. A combined management protocol for patients with coagulation disorders infected with hepatitis C virus
83. Liver biopsy in Irish hepatitis C-infected patients with inherited bleeding disorders
84. Hepatitis in haemophilia
85. The role for liver biopsy in haemophiliacs infected with the hepatitis C virus
86. Investigation of chronic hepatitis C infection in individuals with haemophilia: Assessment of invasive and non-invasive methods
87. Management of hepatitis C in the hemophilia patient
88. Assessment and treatment of liver disease in Japanese haemophilia patients
89. Gastroenterological procedures among patients with disorders of hemostasis: Evaluation and management recommendations
90. A study of liver biopsies and liver disease among hemophiliacs
91. Interferon alpha therapy in haemophilic patients with chronic hepatitis C: A French multicentre pilot study of 58 patients
92. Effect of renal failure on hemostasis
93. Renal biopsy in high-risk patients with medical diseases of the kidney
94. Hemostasis in renal disease: Pathophysiology and management
95. Percutaneous liver biopsy complications in patients with chronic renal failure
96. Noninvasive diagnosis of hepatic fibrosis or cirrhosis
97. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy
98. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection
99. Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis
100. The role of liver biopsy in chronic hepatitis C
101. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis
102. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection
103. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection
104. Progressive liver functional impairment is associated with an increase in AST/ALT ratio
105. Serum type III procollagen peptide, type IV collagen 7S domain, central triple-helix of type IV collagen and tissue inhibitor of metalloproteinases in patients with chronic viral liver disease: Relationship to liver histology
106. Changes in serum fibrogenesis markers during interferon therapy for chronic hepatitis type C
107. Serum hyaluronan as a marker of liver fibrosis
108. Serum laminin and type III procollagen in chronic hepatitis C
109. Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta
110. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response
111. Histopathological evaluation of liver fibrosis: Quantitative image analysis vs semi-quantitative scores. Comparison with serum markers
112. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study
113. Usefulness of a liver biopsy in the evaluation of patients with elevated ALT values and serological markers of hepatitis viral infection: An AIGO study
114. Fibrosis in patients with chronic hepatitis C: Detection and significance
115. Serum hyaluronan as a marker of liver fibrosis in hemophiliacs with hepatitis C virus-associated chronic liver disease